Feed GKOS
GK

Glaukos

GKOS · NYSE

$163.82 +0.40% (+$0.65)
1M -11.51%
Market Cap $9.66B
P/E Ratio -
Div. Yield -
ROE 27.07%

Bulios Fair Price

$149.99

8.4% downside

Current Price

$163.82

Undervalued Fair Value Overvalued

According to Bulios Fair Price, GKOS is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Weak
3/9
Valuation
0 /100
Expensive
P/S 15.77x
P/B 14.16x
P/E N/A
Growth
92 /100
Growing
Rev. growth 21.51%
Book val. growth 7.38%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 79.12%
FCF margin 1.99%
Net margin 30.68%
Quality
8 /100
Poor
ROIC 9.59%
Asset turnover 0.67x
ROE 27.07%
Debt
69 /100
Low
Debt/Equity 0.15x
Int. coverage -38.21x
Current ratio 5.04x
Stability
81 /100
Stable
Beta 0.77x
Profitable years 0
Rev. volatility 10.53%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about GKOS
Online

About the company

Glaukos Corporation is an American biotechnology company focused on the development and manufacture of innovative ophthalmic products. Founded in 1998, its headquarters are located in San Clemente, California. Glaukos specializes in the treatment of glaucoma and other eye diseases using new technologies, including implants and micro-surgical solutions. The company focuses on improving patients' quality of life through groundbreaking products and services that bring innovation to the field of ophthalmology.

Sector

Healthcare

Industry

Medical - Devices

CEO

Thomas William Burns

Employees

1,094

Headquarters

Aliso Viejo

Upcoming events

04 NOV

Earnings

Upcoming earnings report

30d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.